Previous Next


№1' 2014


International Medical Journal, Vol. 20., Iss. 1, 2014, P. 70−74.


Skvortsov V. V., Tumarenko A. V.

Volgograd State Medical University, Ministry of Health, Russian Federation

Viral hepatitis caused by A,B,C,D,E,F,G,TTV, SenV viruses is a highly important medical and social issue. Widespread use of hepatitis B and C diagnosis has shown that every tenth inhabitant of the earth is infected by one of these viruses. Successive treatment of these diseases is determined by both creation of new drugs and development of combinations of these drugs used in clinical practice. Various approaches to etiotropic therapy of chronic viral hepatitis, the leading of which is the use of pharmacological agents, interfetrons (natural, recombinant, short−range and long−acting), are featured. Promising is the use of combination protocols of therapy, i.e. simultaneous administration of interferon and its inductor (for example, interferon and cycloferon) with the purpose to prevent remission escape. As a means of viral hepatitis therapy inhibitors of reverse transcriptase (nucleoside analogues) are used. Plasmid DNA−vaccines are of special concern. The fact that there are patients recovered from acute hepatitis C is reassuring. Understanding the mechanism of clearance can allow to tale a step towards the vaccine creation. At large, viral hepatitis therapy is a difficult task. Drug combinations are the thing of the future, which was proven by the use of such protocol in viral (HIV infection) and nonviral (tuberculosis) diseases.

Key words: viral hepatitis, pharmacotherapy, drug combination.

Go on Top